Monte Rosa Therapeutics宣布MODEFIRE-1研究首位患者完成给药——评估MRT-2359联合阿帕鲁胺治疗AR突变阳性转移性去势抵抗性前列腺癌的II期临床试验

美股速递08-24

Monte Rosa Therapeutics今日宣布，其关键性II期临床试验MODEFIRE-1已迎来首位患者完成给药。这项研究旨在评估MRT-2359与阿帕鲁胺联合用药方案，针对携带AR突变阳性的转移性去势抵抗性前列腺癌（mCRPC）患者的安全性与疗效。

值得关注的是，该联合疗法直指前列腺癌治疗领域一个极具挑战性的亚群——那些尽管接受标准内分泌治疗但肿瘤仍持续进展，且存在雄激素受体（AR）基因突变的人群。MRT-2359作为一种新型靶向药物，其作用机制与阿帕鲁胺的雄激素受体抑制路径形成互补，这一组合策略被认为可能为耐药性肿瘤提供新的破解之道。

本次里程碑式的进展，标志着Monte Rosa Therapeutics在推进精准肿瘤学治疗方面迈出了坚实一步。MODEFIRE-1研究将系统性地评估该联合方案在此类难治性患者群体中的临床获益，为未来更大规模的验证性研究奠定基础。

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohunote.com/m/news/1147230074?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-08-24 19:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1147230074","market":"us","top_or_hot":-1,"title":"Monte Rosa Therapeutics宣布MODEFIRE-1研究首位患者完成给药——评估MRT-2359联合阿帕鲁胺治疗AR突变阳性转移性去势抵抗性前列腺癌的II期临床试验","media":"美股速递","content":"<p>Monte Rosa Therapeutics今日宣布，其关键性II期临床试验MODEFIRE-1已迎来首位患者完成给药。这项研究旨在评估MRT-2359与阿帕鲁胺联合用药方案，针对携带AR突变阳性的转移性去势抵抗性前列腺癌（mCRPC）患者的安全性与疗效。</p>\n<p>值得关注的是，该联合疗法直指前列腺癌治疗领域一个极具挑战性的亚群——那些尽管接受标准内分泌治疗但肿瘤仍持续进展，且存在雄激素受体（AR）基因突变的人群。MRT-2359作为一种新型靶向药物，其作用机制与阿帕鲁胺的雄激素受体抑制路径形成互补，这一组合策略被认为可能为耐药性肿瘤提供新的破解之道。</p>\n<p>本次里程碑式的进展，标志着Monte Rosa Therapeutics在推进精准肿瘤学治疗方面迈出了坚实一步。MODEFIRE-1研究将系统性地评估该联合方案在此类难治性患者群体中的临床获益，为未来更大规模的验证性研究奠定基础。</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Monte Rosa Therapeutics宣布MODEFIRE-1研究首位患者完成给药——评估MRT-2359联合阿帕鲁胺治疗AR突变阳性转移性去势抵抗性前列腺癌的II期临床试验</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMonte Rosa Therapeutics宣布MODEFIRE-1研究首位患者完成给药——评估MRT-2359联合阿帕鲁胺治疗AR突变阳性转移性去势抵抗性前列腺癌的II期临床试验\n</h2>\n\n<h4 class=\"meta\">\n\n2026-08-24 19:01 北京时间&nbsp;&nbsp;&nbsp;<strong>美股速递</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Monte Rosa Therapeutics今日宣布，其关键性II期临床试验MODEFIRE-1已迎来首位患者完成给药。这项研究旨在评估MRT-2359与阿帕鲁胺联合用药方案，针对携带AR突变阳性的转移性去势抵抗性前列腺癌（mCRPC）患者的安全性与疗效。\n值得关注的是，该联合疗法直指前列腺癌治疗领域一个极具挑战性的亚群——那些尽管接受标准内分泌治疗但肿瘤仍持续进展，且存在雄激素受体（AR）...</p>\n\n<a href=\"\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"GLUE","symbol_name":"Monte Rosa Therapeutics","start_time":0,"source_url":"","article_id":"1147230074","we_media_id":"1004306016","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1147230074","pubTimestamp":1787569273,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"美股速递","introduction":"全球快讯第一时间播报","home_visible":1,"id":"1004306016","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Monte Rosa Therapeutics今日宣布，其关键性II期临床试验MODEFIRE-1已迎来首位患者完成给药。这项研究旨在评估MRT-2359与阿帕鲁胺联合用药方案，针对携带AR突变阳性的转移性去势抵抗性前列腺癌患者的安全性与疗效。本次里程碑式的进展，标志着Monte Rosa Therapeutics在推进精准肿瘤学治疗方面迈出了坚实一步。MODEFIRE-1研究将系统性地评估该联合方案在此类难治性患者群体中的临床获益，为未来更大规模的验证性研究奠定基础。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"GLUE":"Monte Rosa Therapeutics","BK4539":"次新股","BK4139":"生物科技"},"translate_title":"Monte Rosa Therapeutics Announces Dosing Completion of the First Patient in the MODEFIRE-1 Study — a Phase II Clinical Trial to Evaluate MRT-2359 Combined with Apalutamide in the Treatment of AR Mutation-Positive Metastatic Castration-Resistant Prostate Cancer","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GLUE":1},"content_text":"Monte Rosa Therapeutics今日宣布，其关键性II期临床试验MODEFIRE-1已迎来首位患者完成给药。这项研究旨在评估MRT-2359与阿帕鲁胺联合用药方案，针对携带AR突变阳性的转移性去势抵抗性前列腺癌（mCRPC）患者的安全性与疗效。\n值得关注的是，该联合疗法直指前列腺癌治疗领域一个极具挑战性的亚群——那些尽管接受标准内分泌治疗但肿瘤仍持续进展，且存在雄激素受体（AR）基因突变的人群。MRT-2359作为一种新型靶向药物，其作用机制与阿帕鲁胺的雄激素受体抑制路径形成互补，这一组合策略被认为可能为耐药性肿瘤提供新的破解之道。\n本次里程碑式的进展，标志着Monte Rosa Therapeutics在推进精准肿瘤学治疗方面迈出了坚实一步。MODEFIRE-1研究将系统性地评估该联合方案在此类难治性患者群体中的临床获益，为未来更大规模的验证性研究奠定基础。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":true,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1147230074","isCrawlerRequest":true}